Floatz logo

ctx131

Esophageal Carcinoma

CRISPR Therapeutics AGPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

40 Active assets in the Esophageal Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
NuCana plc
Phase 3BB
Docetaxel
NuCana plc
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 3B
Capivasertib
National Cancer Institute (NCI)
Phase 2CCC
Thalidomide
Henan Cancer Hospital
Phase 2CCC

View all 50 →

Same molecule, other indications

ctx131 is also rated in:

malignant pleural mesotheliomaDormant
CCC
Indicative ·
52 / 100
View asset →
cervical carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →